Objective: Cardiovascular peptides such as angiotensin II (Ang II) and atrial natriuretic peptide (ANP) have metabolic effects on adipose cells. These peptides might also regulate adipocyte proliferation and visceral adipose tissue (VAT) expansion. Welldifferentiated and stabilized primary cultures of human visceral mature adipocytes (MA) and in vitro-differentiated preadipocytes (DPA) were used as a model to study regulation of VAT expansion. Methods: Adipocyte differentiation was evaluated by Oil Red O staining and antiperilipin antibodies. MA and DPA from intraand retro-peritoneal depots were treated with increasing Ang II (with or without valsartan, a highly selective, competitive, 'surmountable' AT1 antagonist devoid of peroxisome proliferator-activated receptor g agonistic activity) or ANP concentrations. Cell counts and bromodeoxyuridine incorporation were used to evaluate proliferation. Apoptosis was evaluated by Hoechst 33342 staining. 8-Bromo cyclic guanosine monophosphate (8Br-cGMP) was used to investigate ANP effects, and real-time PCR to evaluate Ang II and ANP receptors' expression. Results: Cell proliferation was progressively stimulated by increasing Ang II concentrations (starting at 10À11 M) and inhibited by ANP (already at 10À13 M) in both MA and DPA. Co-incubation with increasing Ang II concentrations and valsartan indicated that Ang II effects were AT1-mediated. Indeed, AT2 receptors were not expressed. Valsartan alone slightly inhibited basal proliferation indicating an autocrine/paracrine growth factor-like effect of endogenous, adipocyte-derived Ang II. 8Br-cGMP experiments indicated that the effects of ANP were mediated by the guanylyl cyclase type A receptor.
Introduction
Obesity is a common condition associated with metabolic syndrome, hypertension and increased global cardiovascular risk.
1 Increased visceral fat is a key factor in the metabolic and cardiovascular abnormalities associated with obesity.
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The pathophysiological link between visceral adiposity and cardiovascular diseases is complex. 3 Recently, many studies have suggested that two antagonistic regulatory systems, the renin-angiotensin-aldosterone system and cardiac natriuretic peptides (NP) are not only involved in the regulation of sodium retention and blood pressure but also in the metabolic aspects of obesity.
3-6
Adipose tissue has the full molecular machinery required for angiotensin II (Ang II) synthesis and signal transduction. Ang II has been shown to stimulate lipogenesis 7 and preadipocyte differentiation. 8 Moreover, Ang II is a trophic factor for adipose tissue growth and development through type 1 receptor (AT1). 9, 10 It is able to induce G 1 -phase progression of the cell cycle of human preadipocytes through AT1 receptor, 9 confirming the well-known growth factor-like effects of Ang II. Visceral adipose tissue (VAT) expansion is a process characterized by an increase of the number as well as size of adipocytes. For more than 20 years it was clearly shown that in vitro-cultured mature unilocular adipocytes are able to become multilocular adipocytes and to undergo cell replication, 11 as it was confirmed later. 12 Because Ang II appears to have a trophic role in adipose tissue expansion, it may also contribute to the development of insulin resistance and type 2 diabetes. The improved insulin sensitivity and the reduced new-onset diabetes incidence in patients treated with angiotensin-converting enzyme inhibitors or AT1 receptor blockers 13,14 may be due to a 'brake' on the rate of VAT expansion.
Despite extensive research, the effects of Ang II on adipocytes is still controversial, probably because of the different models and methodologies used. 15 Contrasting data were obtained with preadipocytes during in vitro differentiation, 16 This study aimed at evaluating the effects of increasing concentrations of Ang II or ANP on visceral adipocyte proliferation that is likely to be involved, in vivo, in the maintenance and the expansion of human VAT. Such investigations were extended on both intra-and extraperitoneal VAT depots. 
Methods

Subjects and adipose tissue samples
Evaluation of cell proliferation
Cells were seeded into six-well plastic supports at a density of 15 000 cells cm The bromodeoxyuridine (BrdU)-based colorimetric immunoassay (Roche, Penzberg, Germany), expressed as optical density, was also used to assess proliferation. 25 Apoptosis was detected by Hoechst 33342 (Molecular Probes, Invitrogen, Eugene, Oregon, USA), and apoptotic nuclei, identified from the altered chromatin, were counted.
Gene expression in cultured adipocytes
Total RNA was extracted from floating MA and in vitro-DPA using Qiagen RNeasy MiniKit (including the RNase-free DNase set; Qiagen, Hilden, Germany). RNA was also extracted from control tissues (normal kidney cortex and whole VAT) after homogenization in guanidine thiocyanate buffer and CsCl gradient modified as reported previously. 
Results
From each patient and each visceral intra-and retroperitoneal depots, we successfully obtained primary cultures from both MA (Figure 1a) and preadipocytes (Figure 1b) . We were able to confirm that DPA (Figure 1c) and MA are still able to undergo cell division in vitro, in the absence of FCS (Figure 1d) .
In serum-free conditions, Ang II was able to stimulate, dose-dependently, cell proliferation (Po0.0001, starting at 
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Ang II concentrations overcame this competitive AT1 blocker. Thus, the Ang II-induced proliferation was AT1-mediated. Indeed, VAT and DPA do not express AT2 receptors, as also reported previously. 27 Finally, ANP effect is mediated by NPRA because NPRA are expressed and 8Br-cGMP induced similar inhibition of growth.
The cell-culture model we used has been widely utilized to study metabolic aspects of human adipocytes, with cells kept under stimulation to store triglycerides into lipid droplets. These stable 'well-fed' primary cultures are likely to resemble VAT adipocytes, which in vivo are stimulated to accumulate triglycerides and to expand in obesity. In these stabilized, lipid-rich conditions, without FCS for many days, mature multiloculate adipocytes (Figure 1a ) are able to proliferate (Figure 1d) , confirming previous suggestions and evidences.
9,11,12 Unilocular adipocytes are not terminally differentiated cells but can revert to multilocular and undergo cell division.
11
Our findings were confirmed in cultures of floating, mature, paucilocular adipocytes, free from contamination of other cell types (for example, fibroblasts or mesenchimal stem cells) that could affect the results. In any case, even if a subpopulation of cells could have a less-differentiated, proliferation-prone phenotype, the general interpretation of the results do not change because VAT expansion in vivo is very likely to depend also on these cells to expand.
Conflicting results have been published previously about the control of adipocyte proliferation and differentiation. Using cultured preadipocytes from human subcutaneous mammary adipose tissue during in vitro differentiation, it has been hypothesized that Ang II might inhibit preadipocyte differentiation reducing formation of new smaller adipocytes, believed to be less insulin-resistant than the larger, older ones. 16 In contrast, starting from mesenchymal stem cells treated with Ang II in the presence of valsartan and/or PD123319, Matsushita et al. 15 showed that differentiation to adipocytes was stimulated by Ang II through AT1 and inhibited through AT2 receptors. Finally, when undifferentiated 9 and fully DPA or MA (our present data) were considered, Ang II showed an AT1-mediated proliferative effect, whereas AT2 resulted in no expression at all. Several considerations may help to explain these discrepancies. First, expression of AT2 receptors is likely to be crucial to explain these contrasting findings. Human mesenchymal stem cells express both AT1 and AT2 receptors and, using this model, Ang II seems to induce adipocyte differentiation through AT1, whereas AT2 play a counteracting action. 15 In summary, the opposing regulatory activities of Ang II and ANP on visceral adipocytes resemble the opposite role that these peptides have on the cardiovascular system. 39 If so, our findings could have a biological relevance that goes beyond the model we used to assess adipocyte growth. A further support of this hypothesis is coming from a recent study that shows an AT1-mediated inhibitory effect of Ang II on lipolysis in human adipocytes, 40 again the opposite effect of ANP.
In conclusion, the antagonistic effects of Ang II and ANP on the proliferation of visceral differentiated adipocytes are likely to be present in human VAT in vivo, suggesting that ANP and Ang II may have important regulatory roles on visceral adipose organ expansion.
